• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Masimo CEO Joe Kiani faces shareholder vote today

Masimo CEO Joe Kiani faces shareholder vote today

September 19, 2024 By Chris Newmarker

Masimo CEO Joe Kiani
Masimo founder, Chair and CEO Joe Kiani [Image courtesy of Masimo]
Masimo (Nasdaq: MASI) shareholders today will decide on a bitter proxy fight between the company’s founder and CEO Joe Kiani and Politan Capital Management.

In July, the digital health pioneer delayed its annual shareholders meeting to Sept. 19, so it had time to sue Politan in federal court in California over accusations of material misstatements in communications to shareholders. The judge eventually ruled that the vote could proceed.

Politan is seeking Kiani’s ouster more than a year after it won a heated fight for two seats.

Kiani’s board seat is on the line in the shareholders’ vote. Company management is also running Christopher Chavez — a 30-year medtech veteran who previously held CEO roles at Trivascular and Advanced Neuromodulation Systems Inc. (ANSI) — for an independent director slot.  Politan is meanwhile running former Stryker CFO Bill Jellison and former Agilent Technologies SVP and Chief Technology Officer Darlene Solomon for the spots.

Under pressure from Politan, the maker of pulse oximeters, wearable health trackers, and other health monitoring devices has been looking at options to split off its consumer business, undoing a two-year-old $1 billion acquisition of Sound United and its high-end audio and home theater systems.

Masimo has more arguments for its side on protectmasimosfuture.com, while Politan is making its case at www.advancemasimo.com.

Quentin Koffey of Politan Capital Management said in a Sept. 16 letter to shareholders that, “we remain focused on the exceptional opportunity at Masimo and the chance this election represents to make clear that shareholders deserve better.”

Kiani has said he plans to leave the company if he’s ousted from the board. Others including COO Bilal Muhsin and hundreds of engineers have said they would leave, too.

In a Sept. 15 news release, Kiani said: “For more than 35 years, the team at Masimo has poured our heart and soul into driving innovations for patients and value for stockholders. We have internalized our stockholders’ feedback, and we are changing – some of those changes have already been implemented, and others are just around the corner, including the separation of our consumer business and expansion of our Board. This builds on the continued momentum we are driving across Masimo, as demonstrated by our strong second quarter results and recently announced strategic partnerships with companies such as Google and Qualcomm.”

Filed Under: Business/Financial News, Diagnostics, Digital Health, Patient Monitoring, Wall Street Beat Tagged With: Masimo

More recent news

  • Citi downgrades Boston Scientific as cyberattack recovery compounds competitive pressure
  • Autonomix taps former Medtronic FDA counsel head for board of directors
  • Medtronic strengthens robotic surgery position with Cornerstone deal, analysts say
  • Science Corp. names president as it looks to roll out vision-restoring implant
  • Mindray looks to fill hospital ventilator gap left by Philips’ exit

About Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at [email protected].

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy